Dementia Investment Forum 15 April 2015 Queen Mary Innovation Centre, 42 New Road, London E1 2AX
Programme 14.00
Registration and Networking over tea and coffee
14.30 Welcome 14.45
Session 1: Investing in Technology in Dementia
Chair: Ben Newton, GE Healthcare Panellists: Alan Edwards, ASep Healthcare Oliver Sexton, Midven Jill Rasmussen, psi-napse Susan McGoldrick, The CNS Company Nathan Nagel, Health E-Games Company pitches: Pre Diagnostics AS – Erik Christensen Health E-Games – Nathan Nagel Cambridge Cognition – Andrew Blackwell 16.00
Tea and Coffee Break
16.30 Session 2: Investing in Therapeutics in Dementia Chair: Michael Perkinton, MedImmune and AstraZeneca Panellists: Rob Pinnock, MSD Daniel Mahony, Polar Capital Geraldine O’Keefe, Life Science Partners Alasdair Thong, Index Ventures Julie Simmonds, Canaccord Genuity Hakan Goker, MS Ventures
Company pitches: Pharmasum – Anders Fugeli Asceneuron – Dirk Beher Probiodrug – Konrad Glund 17.45
Tea and Coffee Break
18.15 Session 3: How can Public-Private Partnerships Change the Dynamic? Chair: Siro Perez, Roundcape Panellists: Eric Karran, Alzheimer’s Research UK Declan Jones, Johnson & Johnson Innovation Centre Håkon Sæterøy, Pre Diagnostics AS Myra Waiman, Romney Consultants Lisa Urquhart, EP Vantage 19.00
Closing remarks followed by networking over drinks and canapes
20.00
Event closes
Event sponsor
Event host
Speaker Profiles Dirk Beher, CEO, Asceneuron Dirk Beher is the Chief Executive Officer and a founder of Asceneuron SA. He raised the seed funding and established this science-driven biotechnology company as a spin-off from Merck Serono in October 2012.
Dirk spent over 17 years in pharmaceutical drug discovery with a focus on neurodegeneration. He has held various positions with increasing responsibilities at major pharmaceutical and biopharmaceutical companies such as Merck & Co. (MSD), Amgen and Merck Serono in locations around the globe.
Dirk holds a Ph.D. and a Diploma (M.S.) in Biology from the Ruprecht-Karls University Heidelberg, Germany. He is an inventor of seven patents and currently authors 49 peerreviewed publications and reviews.
Andy D Blackwell, CSO, Cambridge Cognition Andy is Chief Scientific Officer at Cambridge Cognition, board advisor to several neurotech companies, and Honorary Researcher at the University of Cambridge. Andy believes that technology can transform our understanding of the environmental and biological determinants of brain health, and will empower us to achieve and maintain peak cognitive form throughout life. He has worked in the field of cognitive assessment for over 20 years, working closely with Professors Trevor Robbins and Barbara Sahakian in the areas of cognitive neuropsychology and psychopharmacology at the University of Cambridge.
His clinical experience includes Alzheimer’s disease, mild cognitive impairment, Parkinson’s disease, Huntington’s disease, stroke, OCD, ADHD and depression. Andy has published numerous papers in quality journals, including Science, American Journal of Psychiatry and Neuropsychopharmacology. Since joining the board of Cambridge Cognition in 2007, Andy has consulted for most of the leading pharmaceutical research organizations and has worked on over 150 clinical trials of investigational drugs targeting disorders of the CNS.
Erik Christensen, CMO/COO, Pre Diagnostics AS Former CEO at DiaGenic ASA for six years with experience of developing blood based molecular diagnostic tests for Alzheimer’s and breast cancer. Dr. Christensen previously worked for 10 years at Abbott Diagnostics, both as Medical Director Nordics and as Country Manager Norway, with particular interest in immunoassays and related diagnostic instruments. He is also currently the chairman of Nansen Neuroscience Network and board member in Norwegian life science companies. His medical background is in clinical chemistry with several senior positions in Norwegian University Hospitals. He also holds a PhD in Medical Biochemistry from the University of Oslo.
Alan Edwards, Chairman & CEO, ASep Healthcare Alan has spent over 40 years in the healthcare industry, both in the UK & USA. Alan has a wide-ranging and comprehensive commercial and technical management background. Having acted as a Chairman, Board member, Managing Director, Chief Executive & Executive Vice President of a number of companies, in 2001, he Founded Credent Ltd, raising £10.5 million of Venture Capital to fund an MBO from CTI Inc. CTI was a NYSE public company co-founded by Alan who sold Credent in 2004 and retired. Since coming out of retirement in 2005, Alan has specialised in developing and growing early stage medical technology companies and has built a personal portfolio of interests including:
• • • • • • • • • •
Sep Healthcare Ltd, a profitable Imperial College Spin-Out Company A Credent Medical Ltd, pain free blood glucose measuring device Dialog Devices Ltd, VEWS device (Vascular Early Warning System) Veryan Medical Ltd, an Imperial College Spin-Out Company ESP Technology Ltd, an investee company from the North West Biomedical Fund developing self-sealing ePTFE Vascular Access grafts Newtec Vascular Products Ltd, a vascular device development company USIT Medical Ltd, dignified urine collection D-Flex, differential-flex fishing rods and golf club shafts Terrence Fredrick Willets Foundation, an arts charity Chairman of the Institute of Directors in North Wales between 2005 and 2008 In 2015, so far Alan has completed three equity investments and assisted in a substantial donation to TFW Foundation charity.
Anders Fugeli, CEO, Pharmasum Therapeutics Dr. Fugelli is the CEO of Pharmasum Therapeutics, a company that discovers and develops novel drugs for the treatment of diseases in the brain, primarily neurology. He has more than 20 years’ experience in research and the pharmaceutical and biotechnology industry. Previous to 2003, he worked in Neurology strategy and commercialisation at GSK, after which, he started working in start-up companies in Norway. His PhD in Neuropharmacology was awarded by Imperial College, London for work carried out at Institut Pasteur, Paris and Preclinical Medical Institute in Oslo. He has received additional training in Corporate Finance at the London Business School.
There is a growing interest in alternative targets for Alzheimer´s disease, and Pharmasum are focusing on one such target, relating to abnormal phosphorylation of the microtubuleassociated protein tau. The main program will enter Lead Optimisation by the end of 2015.
Konrad Glund, CEO, Probiodrug
Dr Konrad Glund has been CEO since 2006 and is the co-founder of Probiodrug. Prior to setting up Probiodrug in 1997, Dr Glund founded IFB Halle GmbH. After Probiodrug sold its DP-4 diabetes assets to (OSI) Pharmaceuticals in June 2004, he joined (OSI) Prosidion, the metabolic subsidiary of (OSI) Pharmaceuticals, based in Oxford, UK, as Chief Operating Officer and Vice President of Business and Corporate Development. During this time at (OSI) Prosidion he helped integrate the diabetes program and has been responsible for several licensing deals with pharma companies. He returned to Probiodrug in 2006 as CEO. Dr Glund holds a PhD in Biochemistry from the Martin-Luther-University of Halle. After completing his studies in biochemistry, he spent about 15 years as an academic lecturer and conducted research in biochemistry as project and team leader at the University of Halle. Dr Glund is author or co-author of over sixty publications and is co-inventor on more than 10 patents.
Hakan Goker, Investment Director, MS Ventures
Hakan Goker (Ph.D.) is a director at MS Ventures, the corporate venture capital fund of Merck Serono. Previously, Hakan was a partner at Aescap Venture which he joined in 2010 investing in European private biotechnology and medical technology companies. Prior to Aescap, he was at Atlas Venture in London until their cessation of European operations. He was instrumental in the creation, financing, business and R&D strategy of various companies including Orphazyme (DK), F Star (NL), Actogenix (BE), Bicycle Therapeutics (UK), Nimbus Discovery (US), Lumavita (CH), Nitec now Horizon Pharma (CH/US), Protaffin (AU/UK), and Egalet (DK). Hakan received his PhD in oncology from the Institute of Cancer Research/ University of London, UK and continued his scientific career with post-doctoral
work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honors, from University College London. Hakan is a board member of Forendo Pharma and Synaffix BV and is acting CBO of Asceneuron SA.
Declan Jones, VP and Neuroscience Lead, Johnson & Johnson London Innovation Centre
Declan Jones, PhD is VP and Neuroscience Lead at the Johnson & Johnson London Innovation Centre (www.jnjinnovation.com). He works with external organisations to find the best approaches to targeting CNS diseases, primarily Alzheimer’s disease and Mood Disorders. Declan is an Executive Team member for the Dementias Platform UK and Wellcome Trust Neuroinflammation Consortium, serves on the Steering Group for the Project Stellar Neurodegeneration Collaboration Project (http://www.stellar-project. be/index.html), and has recently joined the SAB for the South London and Maudsely NHS Foundation Trust BRC at the Institute of Psychiatry, Psychology, and Neuroscience. The London Innovation Centre recently facilitated J&J’s investment in the Global Dementia Investment Fund.
Eric Karran, Director, Alzheimer’s Research UK
Eric joined Alzheimer’s Research UK in 2012 and has responsibility for high-level external representation of our charity as well as driving forward our research strategy. Eric has extensive dementia research experience gained from working in the pharmaceutical industry, holding senior positions in Neuroscience drug discovery research groups (most recently Chief Scientific Officer at Janssen Pharmaceuticals in Belgium), focusing on finding therapeutics for Alzheimer’s disease. He has interacted widely with leading academic groups in the UK, Europe and the USA, as well as working with public funding agencies such as the MRC.
Daniel Mahony, Fund Manager, Polar Capital
Daniel Mahony is a portfolio manager at Polar Capital. He studied biochemistry at the University of Oxford and received his Ph.D. from the University of Cambridge. Daniel moved to California to work as a research scientist at Schering Plough Corporation (now Merck & Co.) in 1995 and made the transition into financial services in 1998, working for ING Barings in New York and Morgan Stanley in London as head of the European healthcare research team. In 2007, he set up Polar Capital’s healthcare team. He has over 20 years of experience within global healthcare covering sectors including biotechnology, medical technology and healthcare services.
Susan McGoldrick, Consultant, The CNS Company
Susan McGoldrick has worked in the pharmaceutical industry in senior executive roles since 1996, initially with a medium sized UK public pharma company and then with a small biotech company that specialized in developing treatments for CNS disorders. Following the sale of this company to its US licensing partner, Susan founded and ran QCTR Ltd, a CRO specialising in conducting clinical trials in CNS indications. QCTR was launched in 2006 and became internationally recognised as an expert in CNS clinical trials. Now part of The Clinical Trial Company and known as The CNS Company, Susan is a consultant to The CNS Company and continues to present on the challenges facing companies developing new treatments for CNS disorders, with a particular interest in clinical trial challenges faced by companies working in dementia clinical trials.
Nathan Nagel, CEO, Health-e-Games Ltd
Innovative executive and leader. CEO of the dementia technology company Health-eGames Ltd and operations director of Dementia Care Nurses CIC. National conference and University speaker on Young Entrepreneurship. Founder of the LifeScience Ventures ltd and Oncology Pharma Ltd. Senior level experience in the global firms Bayer PLC and Takeda PLC. 18 years life science commercial industry experience.
Ben Newton, Executive Director, PET Neurology, GE Healthcare Life Sciences
Ben Newton was appointed Executive Director, PET Neurology, GE Healthcare Life Sciences in January 2014. GE Healthcare Life Sciences is a $4 billion molecular medicine business that provides a broad range of industry-leading technologies and services for drug discovery, pre-clinical and clinical development and biopharmaceutical manufacturing, as well as molecular tools for therapy selection and treatment monitoring in patient care.
Ben joined GE Healthcare as Head of Disease Biology in 2002 from Bayer Healthcare Pharmaceuticals where he set up an R&D department focusing on mechanisms of lung infection and the development of antibiotics. While at Bayer, Ben developed two novel products for the treatment of lung infection and sepsis.
Since joining GE, Ben has held a number of positions of increasing responsibility in the research and development of in vivo diagnostic imaging agents. Ben and his teams have discovered and developed novel imaging agents for the diagnosis and Imaging of fibrosis, Alzheimer’s disease, cardiovascular disease and cancer. Between 2008 and 2012 Ben successfully led several global product development programs to phase III, phase IV and product launch of imaging agents for use in CT, MR and Ultrasound.
Ben has a Bachelor’s degree in Pharmacology and Immunology from the University of Leeds and a PhD in Medicine from Imperial College, London.
Geraldine O’Keeffe, Partner, Life Science Partners
Geraldine O’Keeffe joined LSP in 2008 and became a Partner of the firm in 2010. Geraldine’s prime focus and responsibility within LSP is to invest in listed securities. Prior to joining LSP, she held the position of Senior Healthcare Analyst at Fortis Investment Banking. Geraldine has a very strong scientific background, including a Bachelor’s degree in Biochemistry and Microbiology from University College Cork and a Master’s degree in Biotechnology from University College Galway. She also conducted post-graduate research, Inter Alia, at the prestigious Max Planck Institute for Biophysical Chemistry in Göttingen, Germany. In addition, Geraldine is also a graduate of The Dublin School of Business.
Michael Perkinton, Director, MedImmune and member of Neuroscience IMed, AstraZeneca
Dr Michael Perkinton is a Director at MedImmune, Cambridge, UK. He is also a member of the Neuroscience Innovative Medicines group at AstraZeneca. He has responsibilities for leading pre-clinical drug discovery projects in the neurodegeneration area, and coordinates target discovery and target validation activities. He also oversees numerous research collaborations with academia.
He obtained his first degree in pharmacology from the University of Edinburgh and completed his PhD training in neuroscience from University of London. He then spent more than 15 years in academia as a postdoctoral researcher and research fellow primarily in the
field of neurodegeneration. He has published numerous research articles with a particular focus on understanding the molecular mechanisms underlying Alzheimer’s disease.
Rob Pinnock, Director, Merck Sharp & Dohme
Rob joined MSD’s licensing team in Sept 2007 and since mid-2008 his remit has been to identify partnering opportunities in the UK, Ireland, Portugal & Spain.
Before joining MSD, Rob worked for a year in the University of Cambridge on neuronal injury & prosthetics. He spent time in Biotech between 2004-6, advancing programs in CV, metabolic disease & pain from concept to clinic. Previously he held positions of increasing seniority in Parke Davis, Cambridge, UK, until their acquisition by Pfizer. In 2001, he moved to Pfizer research laboratories in Ann Arbor, Michigan, as senior director for CNS Molecular Science. Collaborations were an important part of Rob’s mandate at Parke-Davis / Pfizer. Before he joined the pharmaceutical industry Rob trained in Southampton & spent several years as a research fellow at the MRC and University of Cambridge.
Jill Rasmussen, Director, psi-napse
Dr. Jill Rasmussen MBCHB, FRCGP, FFPM, Dip Ther, is a clinician with a special interest in psychoses, affective disorders and neurodegenerative diseases. She worked in the pharmaceutical industry for ten years, where she held senior positions in Beecham then SmithKline Beecham, Wellcome and Lundbeck and specialized in the clinical development, life-cycle management and registration of new drugs for psychiatry and neurology.
During her time in the pharmaceutical industry and as a consultant, she has been involved in the development and registration of SSRIs, SNRIs and novel mechanisms in depression and anxiety spectrum indications; symptomatic and disease-modifying therapies for dementias; anticonvulsants for epilepsy, bipolar disorder and neuropathic pain; atypical antipsychotics in schizophrenia and bipolar disorder; dopamine agonists and novel treatments in Parkinson’s disease, novel treatments for sleep disorders and autistic spectrum disorders as well as NCEs for ALS and multiple sclerosis.
She has worked with the Medicines Control Agency (now the MHRA) as a Senior Medical Assessor for 18 months. In 1999 in recognition of her contribution to CNS research she became a Fellow of the Faculty of Pharmaceutical Physicians. In addition, she is an advisor to several venture capital groups and is also a member of the Wellcome Trust Technology Transfer Challenge Committee
Since 1994, she has combined part-time clinical practice (where she is a specialist in community neurology, psychiatry and learning disability) with her own independent research consultancy psi-napse (www.psi-napse.com). This specialises in advising about developmental and medico-marketing strategy for drugs in CNS indications. In the NHS, she has good knowledge of the “new NHS” including expertise in commissioning.
Håkon Sæterøy, CEO, Pre Diagnostics AS
With more than 25 years of experience in management, corporate finance and business development, Sæterøy is shareholder and board member of several life science companies in Norway. He is a board member of Nansen Neuroscience Network (Chairman from 2010 – 2012) and was a board member of Oslo Cancer Cluster (2007 - 2014). Sæterøy was Executive Chairman of DiaGenic ASA from 2002 to 2010. He has a Master of Science in Business from NHH in Bergen, Norway.
Julie Simmonds, Equity Analyst, Canaccord Genuity
Julie’s research coverage encompasses small/mid-cap healthcare companies across medical devices, biotechnology and healthcare services subsectors. Julie joined from Piper Jaffray where she spent five years as a Senior Analyst in the No.1 Extel rated healthcare team, covering UK and European stocks. Prior to Piper Jaffray, Julie was with Nomura and previously Head of Life Sciences Research at Evolution Securities where she was an analyst from 1998 to 2004. Julie has a PhD in Microbiology from University of Kent at Canterbury. Prior to the City, Julie worked in the biotechnology sector in both Europe and the US.
Alasdair Thong, Early Stage Investor, Index Ventures
Alasdair focuses on early stage investments in drug development projects in various indications, with a specific focus on finding projects that fit in Index Ventures’ ‘Asset Centric’ strategy. Before joining Index, Alasdair gained experience with three healthcare startups in strategy and business development roles. He previously worked in the corporate and capital markets teams at Baker & McKenzie and Sidley Austin.
Alasdair graduated with a BA in Law and Chinese from the School of Oriental and African Studies, University of London, and holds an MPhil in Bioscience Enterprise from the University of Cambridge.
Lisa Urquhart, Editor, EP Vantage
A journalist with more than a decade of experience, Lisa joined Evaluate’s EP Vantage as editor after seven years at the Financial Times in London, including time as the biotechnology correspondent, where she generated a number of exclusives. An active contributor to industry panels and articles, Lisa has also commented on the pharmaceutical industry on both television and radio.
Myra Waiman, Consultant, Romney Consultants
Myra Waiman, biochemist and serial Entrepreneur, runs a business and strategy consultancy Romney Consultants and is executive chairman of Infi-tex, (textile pressure sensors). She specialises in technology, medical devices and biotechnology based companies and is non exec director of Stabilitech. Myra has also helped several charities and companies raise funds both in the UK and abroad (including Neurotrope) and is trustee of British Heart Stem Cell Foundation, Weizmann Institute (UK) and Prism The Gift Fund
Neurotrope Bioscience is a speciality bio pharmaceutical company based in the U.S. , developing novel therapies for rare diseases and Alzheimer’s disease, using Bryostatins. It has completed phase 2a for early onset Alzheimer’s disease with positive results.
Delegate List First name Richard Mohammed Leonard John Nick Giles William Dirk Romain Will Morris Simon Andrew Damian Paul Sophie Jason Simon Robin Naomi Iphigenie Erik Bjorn Mary Lucy Rachel Mick Paul Bob Lee Barbara Alan Alexia Robert Vincent Alberto Anders Philippa Vassilis Konrad Hakan Amir Denise
Surname Adams Aiyaz Anderson Ansell Ayers Balleny Beckett Beher Bejot Bentall Berrie Bishop Blackwell Bond Branthwaite Brayne Brown Bury Campbell Chandler Charatsi Christensen Christianson Clark Codrington Colman Cooper Cronin Damms Dawson Domayne-Hayman Edwards Faure Forster Foster Frangini Fugeli Gardner Georgiadis Glund Goker Golbang Goldman
Company Roundcape Ltd. Kemuri TranScrip Partners Sequani Ltd Stifel Hip Impact Protection Ltd Asceneuron ImaginAb LA Design TTS Ltd Clinical Network Services Pty Ltd Cambridge Cognition Ltd CellCap Technologies Limited TranScrip Partners IP Pragmatics Limited Ubiquigent SYNthesis med chem Beaufort Sciences University of Manchester Public Health England PreDiagnostics AS UCL Hume Brophy Edison Investment Research MRC Technology Edison Investment Research Clinical Network Services Pty Ltd UKTI - Venture Capital Unit Astex Pharmaceuticals Mercury Bioscience Consultants Ltd Asep Healthcare Hume Brophy Newcastle University University of Cambridge Pharmasum Edison Investment Research Roundcape Ltd. Probiodrug MS Ventures Canadian High Commission UCL
Gerard Eva Deborah Ann Elizabeth Paul Nastaran Mike Nasir Rebecca Declan Tony Priya Pradyp Eric Yvonne Arthur Amanda Inge Melissa Daniel Ipshita Olivia Maria-Joao Ursula Supriya Niall Alun Ciara Susan Hannah Mike Nathan Ben Deirdre Geraldine Maria Kerstin Varuni David Siro Michael Rob Martyn Jill Ramsay Henrijette
Gregg-Smith Haas Harland Hayes Hookham Hopkins Hornett Hurst Hussain Jarvis Jones Jones Kalia Kanabar Karran Kennard Lallement Lehmann Lues Maczka Mahony Mandal Manser Martins Mason Mathur McAlister McCarthy McCarthy McGoldrick Merriman Minett Nagel Newton O'Brien O'Keefe Papademetriou Papenfuss Paranavitane Parry Perez Perkinton Pinnock Postle Rasmussen Richmond Richter
GGS Associates Hume Brophy SR One Ltd The Ann Hayes Consultancy Ltd MRC Technology King's College London Queen Mary BioEnterprises Ltd Kemuri Strategy Foresight Partnership LLP Health Innovation Network Johnson & Johnson Innovation Centre One Nucleus Instinctif Partners Bio-Analytical Technologies (UK) Limited Alzheimer's Research UK CIMYM BioSciences Ltd Retroscreen Virology Ltd MRC Technology Probiodrug South East Health Technologies Alliance Polar Capital Bactevo Ltd Stifel Life Sciences Sharing Ideas Ltd BioDevSolutions Limited Hume Brophy Olswang Adorial Ltd University of Warwick The CNS Company One Nucleus The Positive Ageing Company Health E-Games Limited GE Healthcare Consultant Life Science Partners UCL MRC Technology Osborne Clarke South East Health Technologies Alliance Roundcape Ltd. MedImmune & AstraZeneca MSD Cambridge Healthcare and Biotech Ltd psi-napse Queen Mary BioEnterprises Ltd Sofinnova Partners
Dave Francesca Hakon Emily Oliver Martin Nadia Julie Richard Christopher Kai Alasdair Mark Lisa Saroj Parthiban Hollie Charles Myra Mark Helen
Roberts Sadler SÌterøy Scraggs Sexton Shiderov Shivji Simmonds Smith Stanley Stoeber Thong Treherne Urquhart Velamakanni Vijayarangakannan Vile Waddell Waiman Watling Wise
Selcia Limited Aptuit Ltd PreDiagnostics AS Talisman Therapeutics Ltd Midven Limited UKTI - Investment Services One Nucleus Genuity Synexus Cambridge Healthcare and Biotech Ltd Shionogi Limited Index Ventures Talisman Therapeutics Ltd EP Vantage Fahy Gurteen Laboratories Cambridgene Hume Brophy Pinsent Masons Prism Gift Fund TranScrip Partners UCL